Studying the bone microenvironment may offer new insights into better drugs for fighting prostate cancer metastasis.
With a new first-line approval last year in metastatic prostate cancer, Medivation and Astellas' Xtandi was set up for a head-to-head fight against Johnson & Johnson's Zytiga. Some analysts figured Xtandi would skate to first place. But it hasn't turned out that way--and now, Medivation is putting some more money behind its drug to change course.
SonaCare Medical snagged an FDA OK for its prostate ablation ultrasound device, broadening its international footprint months after ramping up sales for the device in Europe.
Myriad Genetics has inked a three-year contract with Tufts Health Plan to provide its Prolaris biopsy test for members diagnosed with localized prostate cancer.
Private equity group Essex Woodlands has snapped up a 16% stake in surgical peripheral nerve solutions company AxoGen. The company raised $17.5 million to back its existing regenerative medicine products, as well as to develop new candidates for nerves severed during prostate cancer surgery and lower extremity nerve injuries. The financing is expected to put the company in the black for the first time.
Myriad Genetics nabbed Medicare coverage for its prostate cancer screening test, a win for the company as it struggles with waning revenues and increased competition from rivals in the genetic testing market.
Astellas is partnering with both USA Rugby and the Australia Rugby Union for a new prostate cancer campaign. Though it's an unbranded push, the "Pass4Prostate" promotion fits right in with Astellas' stepped-up marketing of Xtandi, the prostate cancer med now approved for previously untreated patients.
Looking to expand its potential market for prostate cancer immunotherapy candidate Prostvac, Bavarian Nordic has announced that it's beginning a Phase II trial for its vaccine in early-stage prostate cancer, representing another possible avenue to broaden the candidate's reach.
Promising research conducted by Dr. Ernest Wright and Dr. Jorge Barrio, both of UCLA's Jonsson Comprehensive Cancer Center, show two types of sodium-dependent glucose transports known as SGLT1 and SGLT2 are actively involved in glucose uptake into tumors. And that makes them prime targets for drug investigators.
Profound Medical went public on the Toronto Stock Exchange last month and raised $25 million in June. Now, it's partnered with Royal Philips to develop its novel, minimally invasive prostate gland ablation tool to be used on Philips' MRI systems.